-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, BridGene Biosciences announced that it has reached a research cooperation agreement with the Peter MacCallum Cancer Center (officially referred to as Peter Mac)
Phenotypic screening is a powerful drug discovery tool that can detect compounds in cell or animal disease models, find those compounds that can cause ideal changes in the phenotype of disease-related cells, and discover new compounds for the treatment of diseases
BridGene's unique IMTAC technology platform can not only discover small molecule ligands for a large number of targets (including "non-drugable" targets) in living cells; it can also be combined with phenotypic screening technology to determine targets that drive phenotypic changes and disease occurrence
▲IMTAC technology platform (picture source: BridGene's official website)
Reference materials:
[1] BridGene Biosciences Announces Research Collaboration with the Peter MacCallum Cancer Centre to Discover Targets and Small Molecule Drug Candidates for Ovarian Cancer.
(WuXi AppTec)